N-(Pyridin-2-yl) arylsulfonamides 1 and 2 (PF-915275) were identified as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. A screen for bioactivation revealed that these compounds formed glutathione conjugates. This communication presents the results of a risk benefit analysis carried out to progress 2 (PF-915275) to a clinical study and the strategies used to eliminate reactive metabolites in this series of inhibitors. Based on the proposed mechanism of bioactivation and structure-activity relationships, design efforts led to N-(pyridin-2-yl) arylsulfonamides such as 18 and 20 that maintained potent 11β-hydroxysteroid dehydrogenase type 1 activity, showed exquisite pharmacokinetic profiles, and were negative in the reactive metabolite assay.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2013.02.066DOI Listing

Publication Analysis

Top Keywords

11β-hydroxysteroid dehydrogenase
12
dehydrogenase type
12
inhibitors 11β-hydroxysteroid
8
strategies eliminate
8
eliminate reactive
8
reactive metabolites
8
n-pyridin-2-yl arylsulfonamides
8
n-pyridin-2-yl arylsulfonamide
4
arylsulfonamide inhibitors
4
type strategies
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!